This is notification that the forty-seventh issue of the Virtual Journal Club (VJC) is available on the International Society of Oncology Pharmacy Practitioners (ISOPP) website. To access it, visit the Virtual Journal Club Surveys page or follow the direct link to the survey. 

 

Journal of Oncology Pharmacy Practice

New treatments for relapsed or refractory acute lymphoblastic leukaemia are showing promise. Immunotherapy mechanisms of action have shown increased response rates. This review of blinatumomab and chimeric antigen receptor T cells is timely. Although traditional toxicities are less, new and significant toxicities include cytokine release syndrome and neurological effects. This review of clinical trial data concludes with a section on the role of pharmacists and pharmacy staff which, when followed, will ensure patients receive the most appropriate care. 

1. Identify cell surface antigens in acute lymphoblastic leukemia that may be targeted with current immunotherapies;
2. Recognize patient populations deriving the most benefit from treatment with chimeric antigen receptor (CAR) T-cell therapy;
3. Describe clinical sequelae of cytokine release syndrome; and
4. Identify optimal strategies to manage toxicities associated with CAR T-cells or blinatumomab.